Our findings demonstrate the ability to detect and quantify PD-L1 protein on bladder cancer patients’ CTCs using an assay with specificity and sensitivity demonstrated in CTC surrogate cell lines. This evidence concerns the gene CD274 and urinary bladder carcinoma.